

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 424B3

MEDICIS PHARMACEUTICAL CORP

Form 424B3

December 13, 2002

Files Pursuant to Rule 424(b) (3)

Registration No. 333-97207

PROSPECTUS SUPPLEMENT NO. 1
To Prospectus dated November 22, 2002

Medicis Pharmaceutical Corporation

2.5% Contingent and Convertible Senior Notes Due 2032
and
Class A Common Stock Issuable Upon Conversion of the Notes

This document supplements our prospectus dated November 22, 2002 (the "prospectus"), relating to \$400,000,000 aggregate principal amount of our 2.5% Contingent Convertible Senior Notes Due 2032 and the Class A common stock issuable upon conversion of the Notes. You should read this prospectus supplement in conjunction with the accompanying prospectus, which is to be delivered by selling securityholders to prospective purchasers along with this prospectus supplement. The information in the following table supplements the information under the caption "Selling Securityholders" in the prospectus.

SELLING SECURITYHOLDERS

Name	Aggregate Principal Amount of Notes that may be sold	Percentage of Notes Outstanding	Class Common Beneficially Owned Proportion of Conversion
Allstate Life Insurance Company	1,600,000	*	*
B.G.I. Global Investors c/o Forest Investment Management L.L.C.	182,000	*	*
Forest Fulcrum Fund L.L.P.	622,000	*	*
Forest Global Convertible Fund Series A-5	2,618,000	*	*
KBC Financial Products USA Inc.	4,088,000	*	*
Lyxor Master Fund c/o Forest Investment Management L.L.C.	586,000	*	*
RBC Alternative Assets L.P. c/o Forest Investment Management L.L.C.	116,000	*	*
Relay 11 Holdings c/o Forest Investment Management L.L.C.	91,000	*	*
S.A.C. Capital Associates, LLC	2,000,000	*	*
Sphinx Convertible Arbitrage c/o Forest Investment Management L.L.C.	46,000	*	*
Sunrise Partners Limited Partnership	8,000,000	2.00	*
WPG Convertible Arbitrage Overseas Master Fund L.P.	2,000,000	*	*
Zurich Master Hedge Fund c/o Forest Investment Management L.L.C.	319,000	*	*
Subtotal	22,268,000	5.56	*

*Less than 1%

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 424B3

- (1) Assumes that any other holders of Notes or any future transferee from any holder does not beneficially own any Class A common stock other than Class A common stock into which the Notes are convertible at the conversion price of 17.2117 shares per \$1,000 principal amount of the Notes.

Investing in the Notes and the Class A common stock issuable upon their conversion involves certain risks. See "Risk Factors" beginning on page 7 of the accompanying prospectus.

Neither the securities and exchange commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus any representation to the contrary is a criminal offense.

The date of this prospectus supplement is December 13, 2002.